Creative Biolabs ADC Blog

Menu

Skip to content
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News

DrugLnk™ Custom Synthesis

Perfect For Business And WooCommerce WordPress Sites

Learn More

Antibody Design and Conjugation

Creative Biolabs provides the most comprehensive antibody design and conjugation services for customized antibody-drug conjugate development

Learn More

Customized ADCs

Creative Biolabs offers a variety of customized ADCs against various cancer targets for antibody-drug conjugate (ADC) development projects.

Learn More

ADC Analysis

Creative Biolabs provides a comprehensive set of in vivo& in vitro analysis services to boost your project research.

Learn More
08May/23

Uptake and Potential Toxicity Mechanism of Non-Target-Dependent ADC—II

May 8, 2023UncategorizedADC, Nonspecific endocytosisbioadc

Nonspecific endocytosis Endocytosis is an important process in cell uptake of nutrients, regulation of transmembrane kinetics, synaptic vesicle recycling, and so on. Endocytosis can also play an important role in the uptakeRead More…

08May/23

Uptake and Potential Toxicity Mechanism of Non-Target-Dependent ADC—I

May 8, 2023UncategorizedNon-Target-Dependent ADC, VC-MMAEbioadc

Linker-Unstable Payload Connection Connector-payload instability can cause the payload to be released prematurely into the bloodstream and lead to ADC miss toxicity. The choice of connectors is one of the main driversRead More…

08May/23

Non-targeted ADC Uptake Matters!

May 8, 2023Uncategorizedantibody-drug conjugatebioadc

So far, a total of 16 ADC drugs have been approved worldwide, and one (trastuzumab duocarmazine) is still in the stage of applying for listing. In recent years, with the significant increaseRead More…

07Apr/23

ADC Combination Therapy: Combining with Immunotherapy

April 7, 2023Antibody-drug Conjugates Research, ReviewADC Combination Therapy, Immunotherapybioadc

Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…

07Apr/23

ADC Combination Therapy: Combining with Targeted Drugs

April 7, 2023Antibody-drug Conjugates Research, ReviewADC Combination Therapy, Targeted Drugsbioadc

Compared to standard chemotherapy, ADC (antibody-drug conjugate) improves the therapeutic index, and its activity in patients with selective tumors makes it a potential partner for targeted drugs. Joint strategies can be conceivedRead More…

07Apr/23

ADC Combination Therapy: Combining with Chemotherapy

April 7, 2023Antibody-drug Conjugates Research, ReviewADC Combination Therapy, Chemotherapybioadc

Although ADC drugs have greatly improved the survival benefits of patients, the duration of their objective response or clinical benefits as a monotherapy is limited due to the emergence of drug resistanceRead More…

02Mar/23

Platinum-Resistant Ovarian Cancer to Create New Drugs! FDA Approved ADC Elahere

March 2, 2023Antibody-drug Conjugates Researchantibody-drug conjugate, DM4, Maytansinoidbioadc

In November 2022, ImmunoGen announced that the Food and Drug Administration (FDA) has accelerated the approval for Elahere (mirvetuximab soravtansine-gynx): a monotherapy for adult patients with epithelial ovarian, fallopian, and primary peritonealRead More…

28Dec/22

ADC Panoramic Overview- Endocytosis of ADC Targeting Antigens

December 28, 2022ReviewADC Targeting Antigens, CD79b, HER2, Trop-2bioadc

CD33 CD33, a 67kda transmembrane glycoprotein receptor, is usually expressed in normal myeloid cells and it is the target of GO because it is preferentially overexpressed in AML cells. The intracellular immunoreceptorRead More…

28Dec/22

ADC Panoramic Overview- endocytosis pathway of ADC

December 28, 2022ReviewAdc Internalization, Endocytosisbioadc

Generally speaking, normal endocytosis can be divided into three stages: (1) bud formation; (2) membrane bending and vesicle maturation; and (3) membrane rupture and release into the cytoplasm. Multiple endocytosis pathways overlap,Read More…

07Dec/22

ADC Overview: Bioconjugation Technology Ⅲ

December 7, 2022ReviewADC, Bioconjugationbioadc

Bioconjugation with engineered unnatural amino acids In addition to the sulfur monoclonal antibody technique, the addition of non-standard amino acids (ncAA) provides another possibility for site-specific conjugation. This technique uses amino acidsRead More…

Posts navigation

  • « Previous
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next »

Categories

Recent Posts

  • Targeting Drug-Resistant Breast Cancer with a Novel ADC
  • Aptamer-Drug Conjugates: The Next Frontier in Targeted Cancer Therapy Shows Encouraging Results
  • A New Hope for Cancer Therapy: How ADCs are Redefining Treatment
  • Hyaluronidase-Conjugated Liposomes May Effectively Target Pancreatic Cancer
  • Beyond the Magic Bullet: How Next-Generation Linkers are Rewriting the ADC Playbook

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs ADC Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Home
  • Antibody-drug Conjugates Research
  • Antibody-drug Conjugates Manufacturing
  • News